Genmab Acquires Merus, Anticipates $1 Billion EBITDA by 2029
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: Globenewswire
- Acquisition Transaction: Genmab's acquisition of Merus at $97 per share has met all conditions, which is expected to accelerate Genmab's shift to a wholly owned model, enhancing revenue diversity and driving sustained growth into the next decade.
- Product Potential: The acquired asset, petosemtamab, is anticipated to launch in 2027 with over $1 billion in annual sales potential, further solidifying Genmab's leadership in antibody therapy development.
- Market Impact: As of December 11, 2025, 94.2% of Merus shares were validly tendered, indicating strong market support for the transaction, which is expected to enhance Genmab's competitive position and investor confidence.
- Subsequent Plans: Genmab will continue to acquire Merus shares during the subsequent offering period ending December 29, 2025, ensuring the completion of 100% equity acquisition, further advancing the company's strategic objectives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
Continue Reading
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
Continue Reading